Figure 8.

The administration of EX527 and C/EBPβ CRISPR reversed the antireactive astrogliosis effect of secukinumab. A‐E, The representative bands and quantitative analysis of SIRT1, GFAP, CyclinD1, PCNA intervened with EX527; F‐K, The representative bands and quantitative analysis of C/EBPβ, SIRT1, GFAP, CyclinD1, and PCNA intervened with C/EBPβ CRISPR activation plasmid. ^* P < 0.05 vs Sham, ^@ P < 0.05 vs vehicle, ^& P < 0.05 vs secukinumab + DMSO, ^# P < 0.05 vs secukinumab, ^$ P < 0.05 vs secukinumab + CRISPR diluent, ^$ P < 0.05 vs secukinumab, mean ± SD, one‐way ANOVA, Tukey's test, n = 6/group. C/EBPβ, CCAAT/enhancer binding proteins beta; CRISPR, clustered regularly interspaced short palindromic repeats; DMSO, dimethyl sulfoxide; GFAP, glial fibrillary acidic protein; GMH, germinal matrix hemorrhage; PCNA, proliferating cell nuclear antigen; SIRT1, silent information regulator 1